Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28274305 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL28104840 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL21899521 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL18249688 | 1.00 | CA2 (0.46) | CA2SLC34A1KDM4EMMP2THRB | |
| Phosphoric Acid SCHEMBL545288 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL11076118 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL499999 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL29104840 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL122024 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL7127167 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147680-A1 | METHOD FOR RECOVERING LITHIUM FROM WASTE PRIMARY LITHIUM BATTERY LEACHATE AND PRODUCING LITHIUM CHLORIDE THEREFROM | 한국지질자원연구원 | 2024-07-11 | — | — | WO | disclosed |
| CN-116355039-A | Method for efficiently harvesting dry matters from soybean protein water | 大连海洋大学 | 2023-06-30 | — | — | CN | disclosed |
| US-9938333-B2 | Modified leptin polypeptides and their uses | AMBRX, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-3216800-A1 | MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| CN-107022020-A | The animal erythropoietin polypeptides and its purposes of modification | AMBRX公司 | 2017-08-08 | — | — | CN | disclosed |
| US-9644014-B2 | Modified animal erythropoietin polypeptides and their uses | AMBRX, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2342223-B1 | MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3103880-A1 | MODIFIED LEPTIN POLYPEPTIDES AND THEIR USES | Ambrx, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2247743-B1 | MODIFIED LEPTIN POLYPEPTIDES AND THEIR USES | AMBRX INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-9260472-B2 | Modified human four helical bundle polypeptides and their uses | AMBRX, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-7128913-B2 | Erythropoietin conjugates | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| WO-2005074650-A2 | MODIFIED HUMAN FOUR HELICAL BUNDLE POLYPEPTIDES AND THEIR USES | AMBRX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| CN-1527726-A | Erythropoietin conjugates | - | 2004-09-08 | — | — | CN | disclosed |
| US-20040147431-A1 | Erythropoietin composition | PAPADIMITRIOU APOLLON | 2004-07-29 | — | — | US | disclosed |
| CN-1429116-A | Novel pharmaceutical composition | HOFFMANN LA ROCHE (CH) | 2003-07-09 | — | — | CN | disclosed |
| US-20030120045-A1 | Erythropoietin conjugates | BAILON PASCAL SEBASTIAN (US) | 2003-06-26 | — | — | US | disclosed |
| US-6583272-B1 | Protein conjugate for use in the treatment of blood disorders | HOFFMANN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| US-20020115833-A1 | Erythropoietin conjugates | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | US | disclosed |
| US-20020037841-A1 | Erythropoietin composition | HOFFMANN-LA ROCHE, INC. | 2002-03-28 | — | — | US | disclosed |
| US-6340742-B1 | GLYCOSYLATED HUMAN ERYTHROPOIETIN AMIDE LINKED TO ORGANOSULFIDE; COVALENTLY BONDED TO POLYOXYETHYLENE GLYCOL END CAPPED WITH LOWER ALCOHOL; BONE MARROW INCREASES PRODUCTION OF RETICULOCYTES AND ERYTHROCYTES | ROCHE DIAGNOSTICS GMBH (DE) | 2002-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147431-A1 | Erythropoietin composition | EPOR, HAMP, HBZ | CA2 805/4885SLC34A1 239/4885KDM4E 2852/4885 |
| US-20020115833-A1 | Erythropoietin conjugates | EPOR, HBG2, HBG1 | CA2 3611/4885SLC34A1 3369/4885KDM4E 2332/4885 |
| US-20020037841-A1 | Erythropoietin composition | EPOR, HAMP, HBZ | CA2 659/4885SLC34A1 122/4885KDM4E 2856/4885 |
| US-20030120045-A1 | Erythropoietin conjugates | EPOR, HBG2, HBG1 | CA2 3550/4885SLC34A1 3575/4885KDM4E 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.